Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 436

1.

Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.

Wellington K, McClellan K, Jarvis B.

Drugs. 2001;61(8):1185-209. Review.

PMID:
11465877
2.

Reviparin sodium - a new low molecular weight heparin.

Breddin HK.

Expert Opin Pharmacother. 2002 Feb;3(2):173-82. Review.

PMID:
11829731
3.
4.

Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).

Haas S, Breyer HG, Bacher HP, Fareed J, Misselwitz F, Victor N, Weber J; ECHOS Trial Group.

Int Angiol. 2006 Dec;25(4):335-42.

PMID:
17164738
5.

Reviparin sodium clivarine: a review of its therapeutic use.

Gore M, Kelkar P, Rege N, Ross C.

J Indian Med Assoc. 2004 Oct;102(10):589-90, 592. Review.

PMID:
15887830
6.

Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.

Sobieraj DM, Coleman CI, Tongbram V, Chen W, Colby J, Lee S, Kluger J, Makanji S, Ashaye A, White CM.

Pharmacotherapy. 2012 Sep;32(9):799-808. doi: 10.1002/j.1875-9114.2012.01106.x. Epub 2012 Jun 28. Review.

PMID:
22744711
7.

Enoxaparin : A Review of its Pharmacology and Clinical Applications in the Prevention and Treatment of Thromboembolic Disorders.

Buckley MM, Sorkin EM.

Drugs. 1992 Sep;44(3):465-497. doi: 10.2165/00003495-199244030-00010.

PMID:
28634920
8.

Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.

Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.

N Engl J Med. 2001 Mar 1;344(9):626-31.

10.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K; Enoxaparin Clinical Trial Group.

Ann Intern Med. 2001 Feb 6;134(3):191-202.

PMID:
11177331
11.

Patients at risk of venous thromboembolism--clinical results with reviparin.

Kakkar VV, Cohen AT, Mohamed MS.

Thromb Res. 1996;81(2 Suppl):S39-45. Review.

PMID:
8822126
12.
13.

Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.

Samama CM, Vray M, Barré J, Fiessinger JN, Rosencher N, Lecompte T, Potron G, Basile J, Hull R, Desmichels D; SACRE Study Investigators.

Arch Intern Med. 2002 Oct 28;162(19):2191-6.

PMID:
12390061
14.
15.

Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.

Tran AH, Lee G.

Ann Pharmacother. 2003 Nov;37(11):1632-43. Review.

PMID:
14565815
16.

Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.

Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS.

Arch Intern Med. 1999 Jun 14;159(11):1221-8.

PMID:
10371230
17.
18.
19.
20.

Dalteparin: a low-molecular-weight heparin.

Howard PA.

Ann Pharmacother. 1997 Feb;31(2):192-203. Review.

PMID:
9034422

Supplemental Content

Support Center